"Angiotensin II Type 1 Receptor Blockers/pharmacology"[MeSH] - Search Results

Year	Number of Results
1992	1
1995	9
1996	1
1997	1
2000	5
2001	1
2002	5
2003	5
2004	176
2005	435
2006	459
2007	514
2008	568
2009	534
2010	516
2011	411
2012	422
2013	352
2014	309
2015	279
2016	210
2017	208
2018	201
2019	177
2020	151
2021	124
2022	32
2023	16
2024	6

1

Al-Majed AR, Assiri E, Khalil NY, Abdel-Aziz HA. Al-Majed AR, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:159-94. doi: 10.1016/bs.podrm.2015.02.003. Epub 2015 Apr 9. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051686 Review.

2

Clinical pharmacokinetics of losartan.

Sica DA, Gehr TW, Ghosh S. Sica DA, et al. Clin Pharmacokinet. 2005;44(8):797-814. doi: 10.2165/00003088-200544080-00003. Clin Pharmacokinet. 2005. PMID: 16029066 Review.

3

Telmisartan.

Bakheit AH, Abd-Elgalil AA, Mustafa B, Haque A, Wani TA. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2015;40:371-429. doi: 10.1016/bs.podrm.2015.01.003. Epub 2015 Mar 31. Profiles Drug Subst Excip Relat Methodol. 2015. PMID: 26051689 Review.

4

Beneficial effects of Angiotensin II receptor blockers in brain disorders.

Saavedra JM. Saavedra JM. Pharmacol Res. 2017 Nov;125(Pt A):91-103. doi: 10.1016/j.phrs.2017.06.017. Epub 2017 Jul 12. Pharmacol Res. 2017. PMID: 28711402 Review.

5

The angiotensin II type 1 receptor blocker valsartan in the battle against COVID-19.

de Ligt M, Hesselink MKC, Jorgensen J, Jocken JWE, Blaak EE, Goossens GH. de Ligt M, et al. Obesity (Silver Spring). 2021 Sep;29(9):1423-1426. doi: 10.1002/oby.23221. Epub 2021 Aug 2. Obesity (Silver Spring). 2021. PMID: 33955183 Free PMC article. Clinical Trial.

6

Association of Angiotensin II Type 1 Receptor Agonistic Autoantibodies With Outcomes in Patients With Acute Aortic Dissection.

Wu XW, Li G, Cheng XB, Wang M, Wang LL, Wang HH, Yang JY, Hu XJ. Wu XW, et al. JAMA Netw Open. 2021 Oct 1;4(10):e2127587. doi: 10.1001/jamanetworkopen.2021.27587. JAMA Netw Open. 2021. PMID: 34596673 Free PMC article.

7

Long-lasting angiotensin type 1 receptor binding and protection by candesartan: comparison with other biphenyl-tetrazole sartans.

Vauquelin G, Fierens F, Van Liefde I. Vauquelin G, et al. J Hypertens Suppl. 2006 Mar;24(1):S23-30. doi: 10.1097/01.hjh.0000220403.61493.18. J Hypertens Suppl. 2006. PMID: 16601569 Review.

8

Current topics in angiotensin II type 1 receptor research: Focus on inverse agonism, receptor dimerization and biased agonism.

Takezako T, Unal H, Karnik SS, Node K. Takezako T, et al. Pharmacol Res. 2017 Sep;123:40-50. doi: 10.1016/j.phrs.2017.06.013. Epub 2017 Jun 23. Pharmacol Res. 2017. PMID: 28648738 Free PMC article. Review.

9

The angiotensin II type 1 receptor blocker azilsartan can overwhelm the sympathetic nerve activation stimulated by coadministration of calcium channel blockers.

Fukuda M, Isobe-Sasaki Y, Sato R, Miura T, Mizuno M, Ono M, Kiyono K, Yamamoto Y, Hayano J, Ohte N. Fukuda M, et al. J Renin Angiotensin Aldosterone Syst. 2019 Jan-Mar;20(1):1470320319839525. doi: 10.1177/1470320319839525. J Renin Angiotensin Aldosterone Syst. 2019. PMID: 30915878 Free PMC article.

10

The role of angiotensin II type 1 receptor antagonists in elderly patients with hypertension.

Thomas GN, Chan P, Tomlinson B. Thomas GN, et al. Drugs Aging. 2006;23(2):131-55. doi: 10.2165/00002512-200623020-00004. Drugs Aging. 2006. PMID: 16536636 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

5,437 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

5,437 results

Results by year